Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sinopharm Group Co ( (HK:1099) ) just unveiled an update.
Sinopharm Group Co. Ltd. has announced a domestic shareholders’ class meeting to discuss a special resolution granting the Board a mandate to repurchase up to 10% of its H Shares. This move is aimed at enhancing capital management flexibility and potentially improving shareholder value, reflecting the company’s strategic focus on optimizing its capital structure.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. is a leading company in the pharmaceutical industry, primarily engaged in the distribution and retail of pharmaceutical and healthcare products. The company operates in the People’s Republic of China and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 7,707,441
Technical Sentiment Signal: Sell
Current Market Cap: HK$57.82B
For a thorough assessment of 1099 stock, go to TipRanks’ Stock Analysis page.